[Biological therapy in idiopathic inflammatory myopathies].

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Orvosi Hetilap

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1556/OH.2014.29787PMID 24379090
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pilot Study of Etanercept in Patients With Refractory Juvenile Dermatomyositis

  2014cited by this paper
• The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study.

  2013cited by this paper
• Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies.

  2013cited by this paper
• Response of Mucocutaneous Lesions to Rituximab in a Case of Melanoma Differentiation Antigen 5-Related Dermatomyositis

  2013cited by this paper
• Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up

  2013cited by this paper
• Myositis in a patient with familial Mediterranean fever and spondyloarthritis successfully treated with anakinra.

  2013cited by this paper
• [Inclusion body myositis--a rarely recognized disorder].

  2013cited by this paper
• Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review.

  2013cited by this paper
• Update in juvenile myositis

  2013cited by this paper
• Therapeutic advances in myositis

  2012cited by this paper
• Interstitial Lung Disease in Myositis: Clinical Subsets, Biomarkers, and Treatment

  2012cited by this paper
• Anti-signal Recognition Particle-positive Juvenile Polymyositis Successfully Treated with Rituximab

  2012cited by this paper
• [Polymyositis/dermatomyositis--clinical picture and treatment].

  2012cited by this paper
• Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome.

  2012cited by this paper
• Efficacy of rituximab in refractory antisynthetase syndrome

  2012cited by this paper
• A randomized, pilot trial of etanercept in dermatomyositis

  2011cited by this paper
• [Inclusion body myositis].

  2011cited by this paper
• Inflammatory myopathies: management of steroid resistance.

  2011cited by this paper
• Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application.

  2011cited by this paper
• Novel autoantibodies and clinical phenotypes in adult and juvenile myositis

  2011cited by this paper
• Therapeutic effect of tocilizumab on two patients with polymyositis.

  2011cited by this paper
• Clinical trials roundup in idiopathic inflammatory myopathies

  2011cited by this paper
• Inclusion body myositis in a patient with long standing rheumatoid arthritis treated with anti-TNFα and rituximab

  2010cited by this paper
• Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis

  2009cited by this paper
• Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis.

  2008cited by this paper
• Open-Label Trial of Anti-TNF-α in Dermato- and Polymyositis Treated Concomitantly with Methotrexate

  2008cited by this paper
• A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies

  2008cited by this paper
• Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: A case report.

  2008cited by this paper
• Alemtuzumab (Campath-1H) for treatment of refractory polymyositis.

  2008cited by this paper
• B cells as therapeutic targets in autoimmune neurological disorders

  2008cited by this paper
• [Rituximab in patients with rheumatoid arthritis: systematic review].

  2007cited by this paper
• Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies.

  2007cited by this paper
• Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients

  2006cited by this paper
• Use of etanercept in the treatment of dermatomyositis: a case series.

  2006cited by this paper
• Treatment of recalcitrant dermatomyositis with efalizumab.

  2006cited by this paper
• The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.

  2006cited by this paper
• New monoclonal antibodies in renal transplantation.

  2003cited by this paper
• The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma.

  2003cited by this paper
• The role of biomechanical factors and HLA-B27 in magnetic resonance imaging-determined bone changes in plantar fascia enthesopathy.

  2002cited by this paper
• Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody.

  2002cited by this paper
• Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis.

  2000cited by this paper
• High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study

  2000cited by this paper
• Levels of cytokine inhibitors: a possible marker of disease activity in childhood dermatomyositis and polymyositis.

  1997cited by this paper
• Treatment of inclusion-body myositis with IVIg

  1997cited by this paper
• Treatment of dermatomyositis with intravenous gammaglobulin.

  1991cited by this paper
• Polymyositis and dermatomyositis (first of two parts).

  1975cited by this paper

• University of Southern Denmark HTA Implementation Roadmap in Central and Eastern European Countries

  2016cites this paper